NFKB1 and renal cell carcinoma: Since inflammation and ROS production are hallmarks of tumoral processes in general [17], and of RCC in particular, the present work shows how the treatment with β-blockers decreases inflammatory targets of the NF-κB pathway and increases the expression of ROS processing enzymes, leading to a decrease in the content of ROS.